{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_version in Record Version (approximate match)
Status:
Possibly Marketed Outside US
First approved in 1995
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Dara Cream (28.5g) by Hi Nature Co., Ltd.
(2016)
Source URL:
First approved in 1988
Source:
CONDITION AND ENHANCE EXFODERM FORTE by OMP, INC.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M017
(2018)
Source URL:
First approved in 1984
Source:
ANDA209351
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Buddate Reges Intensive Treatment by Buddate Co Ltd
Source URL:
First approved in 1982
Source:
NDA018060
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 1977
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 358B
(2010)
Source URL:
First approved in 1976
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 1974
Source:
Absorbine Hooflex Therapeutic Conditioner by W. F. Young, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2017)
Source URL:
First approved in 1966
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04675359: Phase 4 Interventional Unknown status Knee Osteoarthritis
(2021)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02496988: Phase 4 Interventional Not yet recruiting Cytokine-Induced Killer Cells
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE